Granted Patent
B2
US 12,661,507 · App. 17/716,431 · Granted Jun 23, 2026
Methods of treating neurodegenerative disorders with alternating electric fields
Inventors:
Tali Voloshin-Sela (Haifa, IL); Lilach Avigdor (Haifa, IL); Eyal Dor-On (Haifa, IL); Moshe Giladi (Haifa, IL); Hila Fishman (Haifa, IL)
Assignee:
Novocure GmbH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of treating a neurodegenerative disorder in a subject are provided by applying alternating electric fields to the brain of the subject, optionally also administering a drug for treatment of the neurodegenerative disorder (e.g., Alzheimer's disease, Parkinson's disease, dementia) to the subject. In some instances, the neurodegenerative disorder can be treated by applying alternating electric fields to a brain of the human subject wherein the brain is tumor-free.
Claims (8)
1 . A method of treating a neurodegenerative disorder in a subject consisting essentially of applying alternating electric fields to a brain of the subject to reduce activity of GSK3β, wherein the alternating electric fields have an intensity of 1 V/cm to 20 V/cm (RMS) and a frequency between 50 kHz and 1 MHz, and wherein the neurodegenerative disorder is Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), dementia, or Parkinson's disease.
2 . The method of claim 1 , wherein the applying step has a duration of at least 24 hours.
3 . The method of claim 1 , wherein the applying step has a duration of at least 72 hours.
4 . The method of claim 1 , wherein the applying step has a duration of at least 30 days.
5 . The method of claim 1 , wherein the intensity is 1.0 V/cm to 2.5 V/cm (RMS).
6 . The method of claim 1 , wherein the brain is tumor-free.
7 . The method of claim 1 , further comprising diagnosing the subject with a neurodegenerative disorder.
8 . The method of claim 1 , wherein the subject is not diagnosed as having a tumor prior to applying the alternating electric fields.
Assignments (2)
PATENT SECURITY AGREEMENT
Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 8, 2022
From: VOLOSHIN-SELA, TALI; AVIGDOR, LILACH; DOR-ON, EYAL; GILADI, MOSHE; FISHMAN, HILA
To: NOVOCURE GMBH
Reel/Frame 060459/0611 →
Continuity (2)
Provisional Application
63172275
· Apr 8, 2021
References Cited (129)
US 5233987A
· Fabian et al.
· 1993
[cited by applicant]
US 6868289B2
· Palti
· 2005
[cited by applicant]
US 7016725B2
· Palti
· 2006
[cited by applicant]
US 7089054B2
· Palti
· 2006
[cited by applicant]
US 7136699B2
· Palti
· 2006
[cited by applicant]
US 7333852B2
· Palti
· 2008
[cited by applicant]
US 7467011B2
· Palti
· 2008
[cited by applicant]
US 7519420B2
· Palti
· 2009
[cited by applicant]
US 7565205B2
· Palti
· 2009
[cited by applicant]
US 7565206B2
· Palti
· 2009
[cited by applicant]
US 7599745B2
· Palti
· 2009
[cited by applicant]
US 7599746B2
· Palti
· 2009
[cited by applicant]
US 7706890B2
· Palti
· 2010
[cited by applicant]
US 7715921B2
· Palti
· 2010
[cited by applicant]
US 7805201B2
· Palti
· 2010
[cited by applicant]
US 7890183B2
· Palti et al.
· 2011
[cited by applicant]
US 7912540B2
· Palti
· 2011
[cited by applicant]
US 7917227B2
· Palti
· 2011
[cited by applicant]
US 8019414B2
· Palti
· 2011
[cited by applicant]
US 8027738B2
· Palti
· 2011
[cited by applicant]
US 8170684B2
· Palti
· 2012
[cited by applicant]
US 8175698B2
· Palti et al.
· 2012
[cited by applicant]
US 8229555B2
· Palti
· 2012
[cited by applicant]
US RE43618E
· Palti
· 2012
[cited by applicant]
US 8244345B2
· Palti
· 2012
[cited by applicant]
US 8406870B2
· Palti
· 2013
[cited by applicant]
US 8447395B2
· Palti et al.
· 2013
[cited by applicant]
US 8447396B2
· Palti et al.
· 2013
[cited by applicant]
US 8465533B2
· Palti
· 2013
[cited by applicant]
US 8706261B2
· Palti
· 2014
[cited by applicant]
US 8715203B2
· Palti
· 2014
[cited by applicant]
US 8718756B2
· Palti
· 2014
[cited by applicant]
US 8764675B2
· Palti
· 2014
[cited by applicant]
US 8911342B2
· Dissing
· 2014
[cited by examiner]
US 9023090B2
· Palti
· 2015
[cited by applicant]
US 9023091B2
· Palti
· 2015
[cited by applicant]
US 9039674B2
· Palti et al.
· 2015
[cited by applicant]
US 9056203B2
· Palti et al.
· 2015
[cited by applicant]
US 9440068B2
· Palti et al.
· 2016
[cited by applicant]
US 9655669B2
· Palti et al.
· 2017
[cited by applicant]
US 9750934B2
· Palti et al.
· 2017
[cited by applicant]
US 9910453B2
· Wasserman et al.
· 2018
[cited by applicant]
US 20060167499A1
· Palti
· 2006
[cited by applicant]
US 20070225766A1
· Palti
· 2007
[cited by applicant]
US 20070239213A1
· Palti
· 2007
[cited by applicant]
US 20080208287A1
· Palermo
· 2008
[cited by examiner]
US 20090076366A1
· Palti
· 2009
[cited by applicant]
US 20120283726A1
· Palti
· 2012
[cited by applicant]
US 20160016014A1
· Wagner
· 2016
[cited by examiner]
US 20180001075A1
· Kirson et al.
· 2018
[cited by applicant]
US 20180008708A1
· Giladi et al.
· 2018
[cited by applicant]
US 20190117963A1
· Travers et al.
· 2019
[cited by applicant]
US 20200009376A1
· Chang et al.
· 2020
[cited by applicant]
US 20200108031A1
· Borst et al.
· 2020
[cited by applicant]
US 20200121728A1
· Wardak et al.
· 2020
[cited by applicant]
US 20200146586A1
· Naveh et al.
· 2020
[cited by applicant]
US 20200179512A1
· Giladi et al.
· 2020
[cited by applicant]
US 20200269041A1
· Zeevi et al.
· 2020
[cited by applicant]
US 20200368525A1
· Maag et al.
· 2020
[cited by applicant]
US 20210069503A1
· Tran et al.
· 2021
[cited by applicant]
US 20210199640A1
· Patel et al.
· 2021
[cited by applicant]
US 20210299440A1
· Deslauriers et al.
· 2021
[cited by applicant]
US 20210308446A1
· Alon et al.
· 2021
[cited by applicant]
US 20210346694A1
· Wasserman et al.
· 2021
[cited by applicant]
US 20220161028A1
· Giladi et al.
· 2022
[cited by applicant]
CN 108289930A
· 2018
[cited by applicant]
CN 111655319A
· 2020
[cited by applicant]
JP 2008506464A
· 2008
[cited by applicant]
WO WO2019012556A1
· 2019
[cited by examiner]
WO 2021137094A1
· 2021
[cited by applicant]
Jiang XY, Chen TK, Zhou JT, He SY, Yang HY, Chen Y, Qu W, Feng F, Sun HP. Dual GSK-3B/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery. ACS Med Chem Lett. Feb. 9, 2018;9(3):17…
[cited by examiner]
Cao, Lin, Jin Pu, and Min Zhao. “GSK-3↑
[cited by examiner]
Beitz, “Parkinson's Disease: a review,” Frontiers in Bioscience, S6, pp. 65-74, Jan. 2014.
[cited by applicant]
Cai et al., “Roles of glycogen synthase kinase 3 in Alzheimer's disease,” Current Alzheimer Research, vol. 9, No. 7, pp. 864-879, Jan. 2012.
[cited by applicant]
Credle et al., “GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein,” Cell Death and Differentiation, vol. 22, pp.…
[cited by applicant]
Furlong et al., “The Parkinson's disease gene PINK1 activates Akt via PINK1 kinase-dependent regulation of the phospholipid PI(3,4,5)P3,” Journal of Cell Science, vol. 132, Issue 20, Oct. 2019.
[cited by applicant]
Hooper et al., “The GSK3 hypothesis of Alzheimer's disease,” Journal of Neurochemistry, vol. 104, pp. 1433-1439, Dec. 2007.
[cited by applicant]
International Search Report and Written Opinion issued in application No. PCT/IB2022/053329 dated Jun. 29, 2022.
[cited by applicant]
Llorens-Martin et al., “GSK-3β, a pivotal kinase in Alzheimer disease, Frontiers in Molecular Neuroscience,” vol. 21, No. 7, Article 46, May 2014.
[cited by applicant]
Phiel et al., “GSK-3α regulates production of Alzheimer's disease amyloid-62 peptides,” Naure, vol. 423, pp. 435-439, May 2003).
[cited by applicant]
Sen et al., “Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3β in Alzheimer's disease,” Neuroscience, vol. 117, No. 8, pp. 4418-4427, Feb. 2020.
[cited by applicant]
Soutar et al., “Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain,” Journal of Neurochemistry, vol. 115, pp. 974-983, Sep. 2010.
[cited by applicant]
Uemura et al., “GSK3beta activity modifies the localization and function of presenilin 1,” The Journal of Biological Chemistry, vol. 282, No. 21, pp. 15823-15832, May 2007.
[cited by applicant]
Walsh et al., “Alzheimer's Disease and the Amyloid β-Protein,” Progress in Molecular Biology and Translational Science, vol. 107, pp. 101-124, 2012.
[cited by applicant]
Voloshin et al., “Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics,” Cancers, vol. 12, 3016; doi:10.3390/cancers12103016, Oct. 2020.
[cited by applicant]